Life Biosciences Secures $82M in Series C Funding to Prolong Healthy Lifespan

Life Biosciences, a pioneering company based in Boston, MA, is excited to announce that it has successfully raised $82 million in its latest funding round.

Founded in 2017, Life Biosciences is at the forefront of innovative research aimed at extending healthy human lifespans by directly targeting the biological factors that contribute to aging.

This latest infusion of capital will significantly accelerate our mission to develop groundbreaking therapies that effectively address aging-related diseases, which currently represent critical unmet medical challenges.

Our unique platform approach is centered around targeting three key molecular pathways: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming.

By harnessing the potential of these pathways, Life Biosciences aims to pave the way for medicines that not only prevent and treat age-associated conditions but may also reverse their effects.

The funding will facilitate the expansion of our research initiatives and support the ongoing clinical development of our promising therapeutic candidates.

We are committed to pushing the boundaries of scientific innovation to make a meaningful impact on the health span of individuals worldwide, ensuring that as people age, they can enjoy a higher quality of life.

With gratitude to our investors for their belief in our vision, we look forward to advancing our mission and sharing new breakthroughs in the field of healthy aging.